<DOC>
	<DOCNO>NCT00121121</DOCNO>
	<brief_summary>Intramuscular ( IM ) administration HIV lipopeptide vaccine show able induce HIV-1-specific T cell-mediated immune response . The objective trial evaluate safety immunogenicity LIPO-4 vaccine ( HIV lipopeptides include 4 peptide Gag , Pol , RT Nef HIV-1 protein , peptide link TT ) intradermally ( ID ) compare IM administration .</brief_summary>
	<brief_title>Safety Intradermal Versus Intramuscular Administration HIV Lipopeptides HIV Uninfected Adult Volunteers</brief_title>
	<detailed_description>Dose-sparing strategy use intradermal ( ID ) delivery vaccine may one approach improve vaccine immunogenicity reduce cost vaccine . In study , 68 HIV-negative healthy adult volunteer , 21-55 year old , belong `` Volunteers Vaccine '' network set ANRS , randomize receive week 0 , 4 , 12 , either 3 IM dose 0.5 ml LIPO-4 contain 500 µg peptide ( n= 35 volunteer ) , 3 ID dose 0.1 ml , contain 100 µg peptide ( n=33 volunteer ) . Total follow-up 48 week . Safety assess clinically laboratory test . Participants give diary card record adverse event . HIV-1 immune response assess ELISPOT lymphoproliferative assay week 0 , 2 , 6 , 14 , 24 , 48</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>HIV uninfected Acceptable method contraception female reproductive potential Good general health Signed write inform consent Risk infect HIV virus Uveitis , chronic lyme disease , active syphilis , active mycobacterial disease sarcoidosis Autoimmune disease immunodeficiency Medical history food allergy , Lyell 's Steven Johnson 's disease , unstable asthma Active , generalize eczema chronic urticaria Blood product within 2 month prior first study vaccine administration HIV vaccine prior HIV vaccine trial participation immunomodulator study Vaccines within 30 day prior first study vaccine administration Pregnant Longterm immunosuppressive immunomodulator medication within 6 month first study vaccine administration Blood transfusion within 6 month first study vaccine administration Treated extract pituitary hormone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>HIV Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>